Volker Vallon Selected Research

Experimental Diabetes Mellitus

1/2014	Do tubular changes in the diabetic kidney affect the susceptibility to acute kidney injury?
1/2014	SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
1/2012	Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
1/2009	Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus.
10/2008	Ornithine decarboxylase inhibitor eliminates hyperresponsiveness of the early diabetic proximal tubule to dietary salt.
1/2002	Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Volker Vallon Research Topics

Disease

17	Hyperglycemia 01/2022 - 04/2009
17	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2009
13	Body Weight (Weight, Body) 01/2020 - 04/2009
12	Albuminuria 10/2021 - 09/2006
12	Diabetes Mellitus 01/2020 - 01/2002
11	Hypertension (High Blood Pressure) 10/2021 - 01/2005
11	Fibrosis (Cirrhosis) 01/2020 - 01/2006
10	Hypoxia (Hypoxemia) 10/2021 - 11/2007
9	Inflammation (Inflammations) 12/2021 - 01/2013
9	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 01/2002
7	Chronic Renal Insufficiency 01/2021 - 01/2017
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2018 - 02/2003
6	Experimental Diabetes Mellitus 01/2014 - 01/2002
5	Hypoglycemia (Reactive Hypoglycemia) 10/2021 - 06/2009
5	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2009
5	Heart Failure 01/2018 - 02/2008
4	Kidney Diseases (Kidney Disease) 01/2021 - 07/2011
4	Ketosis 01/2021 - 01/2016
4	Weight Gain 08/2015 - 04/2009
3	Hyperinsulinism (Hyperinsulinemia) 01/2022 - 04/2006
3	Ischemia 01/2020 - 11/2009
3	Hypertrophy 08/2017 - 05/2011
3	Proteinuria 08/2005 - 01/2002
2	Acidosis 12/2021 - 01/2006
2	Renal Insufficiency (Renal Failure) 01/2021 - 01/2021
2	Infections 01/2021 - 01/2021
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 05/2018 - 01/2017
2	Reperfusion Injury 01/2018 - 01/2009
2	Hypokalemia 02/2012 - 08/2005
2	Cardiomegaly (Heart Hypertrophy) 05/2011 - 01/2006
2	Gitelman Syndrome 06/2005 - 09/2004
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2020
1	Alstrom Syndrome 01/2020
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2020

Drug/Important Bio-Agent (IBA)

27	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 04/2009
18	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 09/2010
16	SaltsIBA 08/2017 - 07/2002
8	Blood Glucose (Blood Sugar)IBA 10/2021 - 01/2009
7	SodiumIBA 01/2020 - 09/2010
6	empagliflozinIBA 01/2022 - 01/2014
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2004
6	Sodium-Glucose Transport ProteinsIBA 01/2020 - 01/2014
6	MineralocorticoidsIBA 02/2012 - 08/2005
5	Hypoglycemic Agents (Hypoglycemics)IBA 10/2021 - 02/2014
5	Oxygen (Dioxygen)IBA 10/2021 - 11/2007
5	CreatinineIBA 01/2021 - 08/2005
5	AldosteroneIBA 01/2011 - 09/2004
4	Streptozocin (Streptozotocin)FDA Link 01/2019 - 01/2002
4	Insulin (Novolin)FDA Link 05/2018 - 06/2009
4	Phosphotransferases (Kinase)IBA 02/2012 - 01/2006
4	GlucocorticoidsIBA 02/2012 - 01/2006
4	Adenosine (Adenocard)FDA LinkGeneric 01/2009 - 11/2007
4	Desoxycorticosterone Acetate (DOCA)FDA Link 09/2006 - 08/2005
3	Uric Acid (Urate)IBA 01/2022 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 09/2014
3	ReninIBA 01/2020 - 01/2011
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2020 - 01/2013
3	Lipocalin-2IBA 01/2020 - 01/2013
3	SymportersIBA 12/2019 - 09/2004
3	Rosiglitazone (Avandia)FDA Link 01/2015 - 04/2009
3	ThiazolidinedionesIBA 01/2015 - 04/2009
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2015 - 03/2012
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2014
2	dapagliflozinIBA 01/2022 - 01/2012
2	FructoseIBA 12/2021 - 04/2006
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020 - 01/2018
2	Collagen Type I (Type I Collagen)IBA 01/2020 - 01/2019
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2019 - 01/2002
2	Fibronectins (Fibronectin)IBA 01/2019 - 01/2013
2	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 05/2018 - 01/2013
2	Ketone BodiesIBA 01/2017 - 01/2017
2	ChemokinesIBA 09/2014 - 11/2010
2	Dipeptidyl-Peptidase IV InhibitorsIBA 02/2014 - 10/2012
2	AlbuminsIBA 01/2014 - 01/2002
2	Hormones (Hormone)IBA 02/2012 - 05/2006
2	Purinergic P2Y2 ReceptorsIBA 12/2008 - 11/2007
2	Drinking WaterIBA 12/2006 - 05/2006
2	Protein Isoforms (Isoforms)IBA 01/2006 - 01/2002
2	Protein Kinase C betaIBA 01/2006 - 01/2002
1	BenzbromaroneIBA 01/2022
1	methenamine hippurate (Hiprex)FDA LinkGeneric 01/2022
1	Gliclazide (Diamicron)IBA 01/2022
1	urate transporterIBA 01/2022
1	Sodium-Glucose Transporter 2IBA 01/2022
1	NucleotidesIBA 01/2020
1	CholesterolIBA 01/2020
1	ipragliflozinIBA 01/2020
1	Vasopressins (Vasopressin)IBA 01/2020
1	Sucrose (Saccharose)IBA 01/2020
1	NADPH Oxidase 2IBA 01/2020
1	LithiumIBA 01/2020
1	Angiotensin Receptor AntagonistsIBA 12/2019
1	Member 1 Solute Carrier Family 12IBA 01/2019
1	Phenobarbital (Luminal)FDA Link 01/2019
1	Branched-Chain Amino AcidsIBA 01/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018

Therapy/Procedure

6	Therapeutics 01/2021 - 02/2008
4	Glycemic Control 05/2018 - 09/2010
1	Intravenous Injections 01/2019
1	Injections 05/2018